Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and…

Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer,…

AdvanCell’s abstract “Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant…

During SNMMI 2025, our Chief Medical Officer Anna Karmann was interviewed by Journal of Nuclear…

At the 2025 SNMMI Annual Meeting, Dr. David Pattison presented Lead-212 as a promising alpha-emitter…